Li-Ming Gan is a specialist in non-invasive cardiology with broad clinical skills in cardiovascular diagnostics.电竞外围平台

Since 2009, he has been professor in translational cardiovascular research and drug discovery at Sahlgrenska University Hospital in Göteborg, Sweden. Li-Ming actively runs academic research in the field of cardiovascular phenotyping of patients with ischemic heart disease and heart failure, as well as the development and validation of preclinical translational animal disease models.

Li-Ming joined AstraZeneca 12 years ago, where he established a preclinical translational disease platform in atherosclerosis, cardiovascular (CV) disease and heart failure area during his first five years. In 2007, Li-Ming was appointed as Disease Area 文件夹 Leader and later as Science Director, responsible for bringing new drug projects into the pipeline. Between 2011 and 2013, he was CV Translational Science Director to help transfer early studies into the human setting. Here, he developed novel biomarkers and performed explorative human studies to identify and validate new drug targets.

Li-Ming is currently Vice President of Early Clinical Development in CVRM and is responsible for all clinical activities, including early explorative human experimental work, human target validation and clinical trials up to phase 2b in the cardiovascular space.

The environment has changed dramatically in the last two years, we are much 更多 science focused. We are almost like a university today.

Li-Ming Gan Head of Early Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D
lol外围竞猜

LONG-TERM VISION

lol投注平台

CARDIAC REGENERATION FOR HEART FAILURE

lol投注平台

BUILDING IMAGING TRANSLATIONAL PLATFORM

lol投注平台

TICAGRELOR MODE OF ACTION

lol投注平台

lol投注平台

Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases电竞外围平台

Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Li-Ming Gan, Christer Betsholtz. Science  19 Aug 2016: Vol. 353, Issue 6301, pp. 827-830

Non-invasive imaging of atherosclerosis in mice 电竞外围平台

Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. L Gan, J Grönros, U Hägg, J Wikström, C Theodoropoulos, P Friberg, Fritsche-Danielson R. Atherosclerosis 2007 190 (2), 313-320

Translational coronary flow imaging in mice电竞外围平台

Functional and morphologic imaging of coronary atherosclerosis in living mice using high-resolution color Doppler echocardiography and ultrasound biomicroscopy. J Wikström, J Grönros, G Bergström, L Gan. Journal of the American College of Cardiology 2005 46 (4), 720-727

Proving the adenosine mode of action of ticagrelor.电竞外围平台

Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. J Am Coll Cardiol. 2013: 61(7):723-7. doi: 10.1016/j.jacc.2012.11.032.

I am very stimulated to combine academic work with focused pharmaceutical research, to discover novel therapies that treat human diseases with great unmet medical need.

Li-Ming Gan Head of Early Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

lol投注平台

and help us deliver life-changing medicines 

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.